Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 5Breast Neoplasms 2Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

enzalutamide 6radium Ra 223 dichloride 5Docetaxel 2Abiraterone Acetate 2zimberelimab 1xentuzumab 1sacituzumab govitecan 1quemliclustat 1pembrolizumab 1atezolizumab 1apalutamide 1Standard of Care 1Radium-223 1Prednisone 1Nivolumab 1Ipilimumab 1Drug Therapy 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Prostatic Neoplasms, Castration-Resistant × xentuzumab × Clear all
NCT02204072 2025-07-15

BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)

Boehringer Ingelheim

Phase 1 Completed
120 enrolled 28 charts
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡